A ruling by a Cleveland judge will allow most of the plaintiffs' expert witnesses to testify about the MRI drug Omniscan. The ruling covers hundreds of lawsuits against General Electric's health care unit. More »
GE Healthcare ignored the advice of its own safety experts to "proactively" restrict the use of its imaging drug, Omniscan, after reports in Europe linked the drug to a potentially crippling disease, according to a newly unsealed order in a lawsuit against the company. More »
After a daylong hearing, an FDA advisory panel recommends effectively banning the use of GE's Omniscan and Covidien's Optimark in patients with severe kidney disease. The MRI contrast agents have been linked to a rare but often crippling disease, nephrogenic systemic fibrosis. More »
All 15 Stories (7)updates since last visit
A jury awarded $5 million to a patient and his wife after it found GE Healthcare didn’t adequately warn patients and doctors about the risk of its imaging dye, Omniscan. It was the first case involving the dye to go to trial.
A groundbreaking trial over GE Healthcare's imaging dye Omniscan reveals new evidence that a rare but terrible side effect might have been downplayed. GE says the evidence is being twisted and that it acted ethically.
The last-minute deal keeps confidential company documents that could shed new light on injury claims against GE’s Omniscan drug.
An elderly Minnesota woman and her husband claim General Electric hid the risks of the company’s MRI drug Omniscan, causing her to contract a crippling disease.
In a setback for GE Healthcare, the U.S. Food and Drug Administration has recommended against the use of the contrast agent Omniscan in patients with severe kidney disease.
Danish drug regulators said that GE's health care unit incompletely informed regulators about a patient who died after experiencing adverse effects from the company's MRI drug Omniscan.
A ruling by a Cleveland judge will allow most of the plaintiffs' expert witnesses to testify on GE's MRI drug Omniscan.
GE Healthcare ignored its own safety experts' urging to restrict the use of its imaging drug, Omniscan, after it was linked to a potentially crippling disease, according to papers in a lawsuit against the company.
GE Healthcare and a Danish radiologist have settled a British libel suit in which GE claimed that the radiologist had made damaging statements about GE's MRI imaging drug Omniscan.
In private conversations that alarmed then-Treasury Secretary Henry Paulson, Immelt laid out a different picture of GE’s credit situation, according to Paulson’s new book about the crisis
A case over GE's Omniscan MRI drug fuels a debate over British libel law.
An FDA advisory panel recommends effectively banning the use of GE’s Omniscan and Covidien’s Optimark in patients with severe kidney disease.
An FDA review says MRI imaging drugs may be even riskier for kidney patients than it believed previously.
After issuing a blanket warning about the risk to patients with kidney disease, regulators will reconsider whether to treat some imaging agents differently.
Many MRI patients are injected with a GE dye to enhance images. If they have weak kidneys, they might develop a rare and sometimes fatal disease
In May 2009, GE launched the “Healthymagination” campaign to promote its growing medical division, GE Healthcare.
- Some Vital Statistics
- Sales: $17.4 billion
- Profits: $2.85 billion
- Employees: 46,000
- Products: Imaging machines and diagnostic products, monitoring devices and medical records technology
- Financing: GE Capital lends to many GE Healthcare customers
Nephrogenic Systemic Fibrosis (NSF) is a potentially fatal disease that is characterized by painful swelling and thickening of the skin. There is no known cure or definitive cause for NSF, though it appears to affect only MRI patients who have kidney problems.
Contrast agents are drugs administered by radiologists to improve the visibility of a patient’s internal body structure. Omniscan is one of General Electric’s contrast agents.
While GE argued against restrictions on Omniscan with U.S. regulators, doctors at three U.S. medical centers moved away from Omniscan.